LumaBridge has announced a growth equity investment from Summit Partners

St. Antony and Boston, August 24, 2022 /PRNewswire/ — Lumbridge, (formerly known as Cancer Insight), an oncology-focused clinical research organization (CRO), today announced a majority growth investment from a global investor. Summit Partners. The funding will help LumaBridge continue its work providing best-in-class clinical trial solutions to support emerging biopharma companies working to develop life-changing immuno-oncology therapies.

In Lumabridge 2014, veteran Dr. Founded by George Peeples and Dan Hargrove to help advance the development of novel immunotherapies in the fight against cancer. Based on the founders’ combined 3 decades of experience in academic and military research, LumaBridge serves as a strategic partner to emerging biopharma and biotech companies, providing full outsourced clinical trial support throughout the clinical development timeline.

“Innovative therapies often come from unexpected places, but navigating complex clinical and regulatory pathways can be challenging,” said Dr. George PeoplesFounder and Chief Medical Officer of Lumabridge Dr. “We built LumaBridge to provide expert support for the execution of clinical trials and advance novel immunotherapies that ultimately benefit patients.”

LumaBridge offers comprehensive CRO services, including consulting on clinical development strategy, as well as specialized capabilities in military research. In the 8 years since its inception, LumaBridge has made a significant impact on the development of immuno-oncology therapies, supporting a substantial number of trials and projects for more than 30 clients.

“Speak Partners has a long history of partnering with leading companies in healthcare and life sciences, helping to accelerate their growth and development,” added. Dave BoyleChief Executive Officer of Lumabridge Dr. “We are excited to leverage Summit’s experience and extensive resources as LumaBridge enters a new phase of growth and expands our ability to support a greater number of trials and bring more therapies to market.”

“The pipeline for clinical-stage immuno-oncology therapies is growing, as are the complexity, duration and cost of these trials, which drives the need for outsourced services. In our experience, this is especially true of emerging biotech companies, which are often lacking. Internal resources at home -to run tests in-house,” said Mark Dellar, managing director of Summit Partners, who joined the LumaBridge board of directors. “With a deeply experienced and highly respected team, an extensive research site network, and strong clinical operations capabilities, we believe LumaBridge is strongly positioned to meet this important and growing need. We are proud to partner with the LumaBridge team to support the company.” Persistence effect.”

About LumaBridge

LumaBridge is a specialized clinical research organization (CRO) focused on creating innovative clinical trial solutions for biopharma companies. Founded in 2014 as Cancer Insight, the company provides customized clinical trial guidance, strategic partnerships, and personalized attention to each sponsor, accelerating the development of potential therapies.

LumaBridge will assist in drug development, accelerate treatment for patients, and guide biopharma companies through clinical and regulatory pathways. Builds on the success and experience of an experienced team led by George Peoples. As part of their comprehensive CRO services, LumaBridge provides consultation on trial design and clinical development strategy.

For more information, visit lumabridge.com.

About Summit Partners

Founded in 1984, Peak Partners is a global alternative investment firm currently managing more than $35 billion In capital dedicated to growth equity, fixed income, and public equity opportunities. Summit invests in growth sectors of the economy and has invested in more than 550 companies in healthcare, technology and other growth industries. Notable healthcare and life sciences companies supported by Summit include Advanced Cell Diagnostics, Clontech, Diagnostic Hybrids, Fortis Life Sciences, Integrative DNA Technologies, LakePharma, and Viroclinics Biosciences. Summit houses offices North America and Europe and invests in companies around the world.

For more information, please see www.summitpartners.com or follow LinkedIn.

Contact Information:

Lumbridge
[email protected]

Source Lumabridge

Leave a Comment

Your email address will not be published.